Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

TypePublic
HQNorwood, US
Founded2009
Size (employees)25 (est)
Websitecorbuspharma.com
Corbus Pharmaceuticals was founded in 2009 and is headquartered in Norwood, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Corbus Pharmaceuticals Office Locations

Corbus Pharmaceuticals has an office in Norwood
Norwood, US (HQ)
103 100 River Ridge Dr
Show all (1)
Report incorrect company information

Corbus Pharmaceuticals Financials and Metrics

Corbus Pharmaceuticals Revenue

USD

Net income (Q2, 2018)

(23.8 m)

EBIT (Q2, 2018)

(24.3 m)

Market capitalization (20-Sep-2018)

454.8 m

Closing stock price (20-Sep-2018)

8

Cash (30-Jun-2018)

64.7 m

EV

390.3 m
Corbus Pharmaceuticals's current market capitalization is $454.8 m.
Annual
USDFY, 2017

General and administrative expense

9 m

R&D expense

26 m

Operating expense total

35 m

EBIT

(32.6 m)
Quarterly
USDQ1, 2018Q2, 2018

General and administrative expense

3.1 m6 m

R&D expense

9.8 m20 m

Operating expense total

12.8 m26.1 m

EBIT

(11.9 m)(24.3 m)
Annual
USDFY, 2017

Cash

62.5 m

Current Assets

65.5 m

PP&E

1.4 m

Total Assets

67 m
Quarterly
USDQ1, 2018Q2, 2018

Cash

71 m64.7 m

Current Assets

74.5 m67.6 m

PP&E

2.6 m2.7 m

Total Assets

77.1 m70.3 m
Annual
USDFY, 2017

Net Income

(32.4 m)

Depreciation and Amortization

255.7 k

Accounts Payable

(885.8 k)

Cash From Operating Activities

(27.8 m)
Quarterly
USDQ1, 2018Q2, 2018

Net Income

(11.7 m)(23.8 m)

Depreciation and Amortization

81.9 k206.3 k

Accounts Payable

1.2 m628.2 k

Cash From Operating Activities

(1.6 m)(7.2 m)
USDY, 2018

EV/EBIT

-16.1 x

EV/CFO

-54.5 x

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Corbus Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Corbus Pharmaceuticals News and Updates

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Norwood, MA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endoca…

Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union

– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented

Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory an…

Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update

Norwood, MA, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory an…
Report incorrect company information

Corbus Pharmaceuticals Company Life and Culture

Report incorrect company information